Connect Biopharma Holdings (Connect Biopharma Holdings) Dividends per Share : $0.00 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings Dividends per Share?

Connect Biopharma Holdings's dividends per share for the six months ended in Dec. 2023 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2023 was 0.00. As of today, Connect Biopharma Holdings's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Connect Biopharma Holdings Dividends per Share Historical Data

The historical data trend for Connect Biopharma Holdings's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings Dividends per Share Chart

Connect Biopharma Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Connect Biopharma Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Dividends per Share	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Connect Biopharma Holdings's Dividends per Share

For the Biotechnology subindustry, Connect Biopharma Holdings's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Connect Biopharma Holdings's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's Dividend Yield % falls into.

Connect Biopharma Holdings Dividends per Share Calculation

Dividends paid to per common share.

Connect Biopharma Holdings (NAS:CNTB) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Connect Biopharma Holdings's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.565
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Connect Biopharma Holdings Dividends per Share Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Connect Biopharma Holdings (Connect Biopharma Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

12265 El Camino Real, Suite 350, San Diego, CA, USA, 92130

Website

https://www.connectbiopharm.com

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.